Abstract
Today up to 40% of Crohns disease patients receive a concomitant therapy of TNF blockers in combination with thiopurines or methotrexate. Although data of prospective controlled trails are rare, some recently published studies indicate a more rapid onset of remission and increased mucosal healing following concomitant therapy in short term. However, data confirming the need or benefit of concomitant immunosuppressive therapy once remission has been reached remains unknown. Concomitant therapy lowers TNF-alpha induced immunogenicity, but the question of whether ATI formation also lowers the efficiency of TNF-alpha antagonists has not yet been answered to a level that would justify the use of concomitant immunosuppression. Knowing that immunosuppression increases the risk for opportunistic infections and lymphomas the potential risks and of concomitant therapy must be well balanced against the benefit. This article aims to interpret the available data on the efficiency, immunogenicity, and safety of concomitant therapy in patients under anti-TNF therapy.
Keywords: Immunogenicity, Concomitant therapy, Crohn's disease, Biologics, Inflammatory bowel diseases
Current Drug Targets
Title: Concomitant Use of Immunomodulators with Anti-TNF in Crohns Disease: Yes or No?
Volume: 11 Issue: 2
Author(s): Johannes Meier and Andreas Sturm
Affiliation:
Keywords: Immunogenicity, Concomitant therapy, Crohn's disease, Biologics, Inflammatory bowel diseases
Abstract: Today up to 40% of Crohns disease patients receive a concomitant therapy of TNF blockers in combination with thiopurines or methotrexate. Although data of prospective controlled trails are rare, some recently published studies indicate a more rapid onset of remission and increased mucosal healing following concomitant therapy in short term. However, data confirming the need or benefit of concomitant immunosuppressive therapy once remission has been reached remains unknown. Concomitant therapy lowers TNF-alpha induced immunogenicity, but the question of whether ATI formation also lowers the efficiency of TNF-alpha antagonists has not yet been answered to a level that would justify the use of concomitant immunosuppression. Knowing that immunosuppression increases the risk for opportunistic infections and lymphomas the potential risks and of concomitant therapy must be well balanced against the benefit. This article aims to interpret the available data on the efficiency, immunogenicity, and safety of concomitant therapy in patients under anti-TNF therapy.
Export Options
About this article
Cite this article as:
Meier Johannes and Sturm Andreas, Concomitant Use of Immunomodulators with Anti-TNF in Crohns Disease: Yes or No?, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309948
DOI https://dx.doi.org/10.2174/138945010790309948 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging LHON: Mitochondrial Mutations and More
Current Genomics p53: An Attractive Therapeutic Target for Cancer
Current Medicinal Chemistry Recent Insights on the Medicinal Chemistry of Metal-Based Compounds: Hints for the Successful Drug Design
Current Medicinal Chemistry Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer
Letters in Drug Design & Discovery <i>In Silico</i> Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Atypical GTPases as Drug Targets
Anti-Cancer Agents in Medicinal Chemistry Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets Macrophage Activation Syndrome in Childhood Rheumatic Diseases
Current Rheumatology Reviews EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology Organic Synthesis of C-Prenylated Phenolic Compounds
Current Organic Chemistry Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency
Current Gene Therapy The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Of Man in Mouse: Modelling Human Cancer Genotype-Phenotype Correlations in Mice
Current Genomics Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Ceramidases in Hematological Malignancies: Senseless or Neglected Target?
Anti-Cancer Agents in Medicinal Chemistry Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)